Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma

Gynecologic Oncology

Volumn 122, Issue 1, 2011, Pages 107-110

  Al Barrak, J ^a   Santos, J L ^a   Tinker, A ^a   Hoskins, P ^a   Gilks, C B ^a   Lau, H ^a   Swenerton, K D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Clear Cell Carcinoma; Outcome; Ovarian; Treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMORADIOTHERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLEAR CELL CARCINOMA; FEMALE; HUMAN; OVARY CARCINOMA; OVARY CLEAR CELL CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PALLIATIVE CARE; TOPOTECAN; TREATMENT OUTCOME;

EID: 79957755784     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.03.011     Document Type: Article

References (20)

1. Pather S, Quinn MA. Clear-cell cancer of the ovary - is it chemosensitive? Int J Gynecol Cancer 2005 May-Jun;15(3):432-7.
2. Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 1998 Sep;27(5):650-6. (Pubitemid 29037230)
3. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008 Jun;109(3):370-6.
4. Goff BA. Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease Gynecol Oncol 1996 Mar;60(3):412-7.
5. Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996 Nov 15;78(10):2157-63. (Pubitemid 26367609)
6. Kobel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 2010;116(1):50-6.
7. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000 Jun 1;88(11):2584-9. (Pubitemid 30331967)
8. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007 May;105(2):404-8. (Pubitemid 46590333)
9. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008 Aug;39 (8):1239-51.
10. Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009 Jan;33(1):14-21.
11. DeLair D, Oliva E, Kobel M, Macias A, Gilks CB, Soslow RA. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 2011 Jan;35(1):36-44.
12. Swenerton KD, Santos JL, Gilks CB, Kobel M, Hoskins PJ, Wong F, et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol 2011 Feb;22(2):341-7.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 Jan;45(2):228-47.
14. Rustin GJ, Bast Jr RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004 Jun 1;10(11):3919-26. (Pubitemid 38697628)
15. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006 May 22;94(10):1369-74. (Pubitemid 43772268)
16. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998 Aug;70 (2):255-8. (Pubitemid 28430939)
17. Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 2010 Feb;20(2):240-7.
18. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 2006 Jan-Feb;16(1):52-6.
19. Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 2008 Sep-Oct;18(5):937-42.
20. Nagai Y, Inamine M, Hirakawa M, Kamiyama K, Ogawa K, Toita T, et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2007 Dec;107(3):469-73. (Pubitemid 350160858)